Fundraising Fox

ProJenX

Nissequogue, US · Founded 2021 · Delaware corporation · 1 known investors

projenx.com ↗

ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS). The company was created through a collaboration between nonprofit Project ALS, Medical Excellence Capital, and researchers at Columbia University to develop and commercialize therapeutic candidates including prosetin.

BiotechDeep TechMedical Devicesin /projenx-inc@projenx

Founders & leadership

JP
John PrufetaDirector
EH
Eric HeilDirector
JM
Joni ManciniExecutive Officer
VE
Valerie EstessDirector
BR
Brent R. StockwellChair of the Department of Biological Science, Professor at Columbia University
HW
Hynek WichterleJerry and Emily Spiegel Professor at Columbia University
JE
Jenifer Estess
EL
Emily LowryDirector of Internal Operations at the Project ALS Therapeutics Core at Columbia
AZ
Arie ZaskFacility Manager for the Columbia University Chemical Probe Synthesis Facility

Investors · 1

Medical Excellence Capital✓ verifiedNew York

Reported raises · per SEC filings

Form D private placements
▶$5.1MraisedJan 2022 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John PrufetaDirector
  • Eric HeilDirector
  • Joni ManciniExecutive Officer
  • Hynek WichterleDirector
  • Valerie EstessDirector
Offering amount
$6M
Amount sold
$5.1M
First sale
Dec 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news